Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun;7(4):357-359.
doi: 10.1016/j.jaccao.2025.02.006. Epub 2025 Apr 8.

Fluoropyrimidine Therapy in Gastrointestinal Cancer: Balancing Survival Benefits and Cardiotoxicity Risks

Mohamad Bassam Sonbol  1 , Tanios Bekaii-Saab  2 , Carolyn M Larsen  3
Affiliations
Editorial

Fluoropyrimidine Therapy in Gastrointestinal Cancer: Balancing Survival Benefits and Cardiotoxicity Risks

Mohamad Bassam Sonbol et al. JACC CardioOncol. 2025 Jun.
No abstract available

Keywords: 5-fluorouracil; gastrointestinal cancer; outcomes; risk prediction.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Sonbol has received consulting fees from Novartis (to self) and Boehringer Ingelheim (to his institution); has received institutional research support from Taiho and Eli Lilly. Dr Bekaii-Saab has received institutional research funding from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS; has received consulting fees (to his institution) from Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA, and Merck, and (to self) from Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, Elevar, Illumina, Foundation Medicine, Sanofi, Glaxo SmithKline, and Xilio; has served on independent data monitoring committees or data safety monitoring boards for The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan, and 1Globe; has served on scientific advisory boards for Imugene, Immuneering, Xilis, Replimune, Artiva, and Sun Biopharma; has received royalties from UpToDate; and holds patents licensed to Imugene and Recursion. Dr Larsen has reported that she has no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jaccao.2025.01.019

Similar articles

See all similar articles

References

    1. National Comprehensive Cancer Network NCCN Guidelines: Colon Cancer. 2025. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428
    1. Padegimas A., Carver J.R. How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach. JACC CardioOncol. 2020;2(4):650–654. doi: 10.1016/j.jaccao.2020.06.012. - DOI - PMC - PubMed
    1. Sara J.D., Kaur J., Khodadadi R., et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10 doi: 10.1177/1758835918780140. - DOI - PMC - PubMed
    1. Abiodun A., JC, Welch C., et al. Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer. JACC CardioOncol. 2025;7(4):345–356. - PubMed
    1. Zafar A., Drobni Z.D., Mosarla R., et al. The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm. JACC CardioOncol. 2021;3(1):101–109. doi: 10.1016/j.jaccao.2020.12.005. - DOI - PMC - PubMed

Publication types

LinkOut - more resources